Is it time to ReSET the standard for estrogen receptor testing in breast cancer?

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4101-4103

  Oesterreich, Steffi ^a   Lee, Adrian V ^a   Davidson, Nancy E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; TUMOR MARKER;

BREAST CANCER; CANCER HORMONE THERAPY; EDITORIAL; GENE CLUSTER; GENE CONTROL; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STANDARD; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; METABOLISM; METASTASIS; METHODOLOGY; MORTALITY; NOTE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957957637     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.9864     Document Type: Editorial

References (14)

1. DeSombre ER, Smith S, Block GE, et al: Prediction of breast cancer response to endocrine therapy. Cancer Chemother Rep 58:513-519, 1974
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
4. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
5. Horwitz KB, McGuire WL: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189:726-727, 1975
6. Cui X, Schiff R, Arpino G, et al: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-7735, 2005 (Pubitemid 46291836)
7. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
8. Loi S: Molecular analysis of hormone receptor positive (luminal) breast cancers: What have we learnt? Eur J Cancer 44:2813-2818, 2008
9. Symanns WF, Hatzis C, Sotiriou C, et al: Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111-4119, 2010
10. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005 (Pubitemid 46224172)
11. Yu J, Yu J, Cordero KE, et al: A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia 10:79-88, 2008 (Pubitemid 351170715)
12. Oh DS, Troester MA, Usary J, et al: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656-1664, 2006 (Pubitemid 46622136)
13. Loi S, Haibe-Kains B, Desmedt C, et al: Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239, 2008
14. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991